Canntab Therapeutics Ltd appoints Hamish Sutherland as Strategic Business Consultant

“Mr. Sutherland’s deep operational expertise in the cannabis industry, particularly in the areas of finance, capital markets and corporate strategy, will broaden the skills matrix of the Canntab team, in the purpose of generating one or more transactions to enhance shareholder value,” said Canntab CEO Larry Latowsky.

Canntab Therapeutics Ltd said it has appointed Hamish Sutherland as a strategic business consultant to develop additional sales and distribution channels for the company’s products and to help it secure strategic partnerships in the cannabis industry.

A seasoned veteran of the legal cannabis industry in Canada with over nine years of experience, Sutherland’s past accomplishments include serving as founding COO of Bedrocan Canada Inc., offering over $750 million in value for investors and overseeing the construction and commissioning of two facilities, including a state-of-the-art 52,000 square foot automated facility in suburban Toronto.

READ: Canntab Therapeutics signs affiliate agreement with independent pharmacy owners in Ontario

“We are very pleased to have Hamish join our team. Mr. Sutherland’s deep operational expertise in the cannabis industry, particularly in the areas of finance, capital markets and corporate strategy, will broaden the skills matrix of the Canntab team, with the goal of generating one or more transactions to enhance shareholder value,” said Larry Latowsky, CEO of Canntab, in a statement.

Sutherland is also an officer and director of various public and private cannabis companies in Canada, the United States and Australia, including Indiva Inc., Mera Cannabis Corp., Altopa Inc. and Asterion Cannabis Inc. He holds an MBA from the Schulich School of Business at York University and a degree in Engineering Physics from McMaster University.

Sutherland’s appointment is initially for four months, but can be extended month-to-month for an additional two months. He will receive $5,000 per month and has been issued 40,000 shares of Canntab common stock. In addition, Canntab also granted him 200,000 stock options exercisable at $0.50 per share for a period of four years. He will also be entitled to finder’s fees for any strategic initiative carried out or that he presents to the company.

Contact the author at [email protected]

Mary H. Martino